cyrilzakka/clinical-trials huggingface dataset:
Dexamethasone in the Prevention of Post-spinal Paralytic Ileus After Cesarean Section

Postoperative ileus is a perplexing problem for clinical surgeons. It occurs not only after abdominal surgery but also after any surgery that requires general anesthesia. Postoperative ileus is defined as the dysfunction of gastrointestinal motility after surgery, characterized by a decrease in, or stagnation of, intestinal peristalsis.

Common clinical manifestations include abdominal pain, abdominal distention, nausea, vomiting, delayed flatus, delayed defecation, and inability to consume orally. Postoperative ileus is an uncomfortable experience, enhances the possibility of postoperative complications, prolongs hospital stay, and increases the economic burden. Postoperative gastrointestinal function recovery is of great concern. There is currently an urgent need to improve postoperative recovery of gastrointestinal function. The mechanism of Postoperative ileus varies, including autonomic regulation, inflammatory response, gastrointestinal hormones, and postoperative use of opioid drugs. Surgical gut damage destroys the intestinal barrier, stimulates the sympathetic and parasympathetic nervous systems, and enhances the release of inflammatory factors. These factors precipitate the occurrence of Postoperative ileus. The current use of laparoscopic techniques can reduce incision size and surgical trauma, enabling careful manipulation.

Eligibility Criteria:
Inclusion Criteria:

* •All participants will sign an informed consent prior to inclusion in the study.

  * All patients 18-40 years of full-term singleton pregnancy (37-41 weeks).,
  * American Society of Anaesthesiologists (ASA) classification class I and II scheduled.
  * for elective or semi-elective surgery (category 3 and 4 Caesarean sections).
  * All patients under spinal anesthesia for a Single baby pregnancy of more than 32 weeks will be included in this study.

Exclusion Criteria:

* will be patients' height \< 150 or \> 180 cm.
* Body mass index (BMI) \>35 kg m-2.
* Contraindication or refusal to undergo regional anesthesia.
* any cardiovascular disease including arrhythmias and severe stenotic valvular heart disease.any renal or hepatic diseased patients.
Quadratus Lumborum Block Type 2 Versus Posterior Transversus Abdominus Plane Block

This patient population are at risk of adverse effects secondary to inadequate pain management such as inadequate maternal bonding and late ambulation.

Regional analgesia is preferred due to their opioid sparing effects and reduction in related adverse effects but the analgesia from these blocks is not known which one is superior to the other in the context of cesarean section

The aim of this study is to compare the effect of posterior transversus abdominus plane block and quadratus lumborum type 2 for cesarean delivery.

The transversus abdominus plane(TAP) block provides sensory block from T6 to L1 for lower abdominal surgeries.

Quadratous lumborum type 2 block, the injection is posterior to the quadratus lumborum muscle. This method has the advantage of a more superficial point of injection with better ultrasonographic resolution.

Only one RCT was done in this context by Kalpana Verma and his colleagues comparing quadratus lumborum type 2 and posterior transversus abdominus plane block. That shows marked discrepancy with time to first analgesic request from the quadratus lumborum block in other abdominal surgeries

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists physical status II parturient.
* Singleton pregnancies with a gestation of at least 37 weeks.
* Patients undergoing spinal anesthesia for cesarean deliveryvia a Pfannenstiel incision with exteriorization of the uterus.

Exclusion Criteria:

* Age \< 19 or \> 40 years.
* Height\<150 cm, weight \< 60 kg, body mass index (BMI) ≥35 kg/m2.
* Inability to comprehend or participatein pain scoring system.
* Contraindications to spinal anesthesia (Coagulopathy, increased intracranial pressure, or local skin infection).
* Hypersensitivity to any drugused in the study.
* Hypertensive disorders of pregnancy.
* Renal impairment or other contraindication to non-steroidal anti-inflammatory drugs.
* Significant cardiovascular, renal or hepatic abnormalities.
* Patients with history of opoid intake, drug abusers, psychiatric patients.
The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation Disorders

To evaluate Efficacy and Safety of oral Atorvastatin and Dexamethasone on conservative treatment for Chronic Subdural Hematoma (CSDH) patients with Coagulation Disorders

Study design: Two-arm,Evaluator-blinded study

Subjects: CSDH patients with Coagulation Disorders（Conservative treatment is adopted）

Sample size: 60 cases, 30 in Atorvastatin and Dexamethasone-treated group, 30 in Atorvastatin-treated group.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 and\<90years old, both gender;
2. Long-term antiplatelet and anticoagulant drugs cause Coagulation Disorders;
3. CT scan reveals supratentorial, unilateral or bilateral chronic subdural hematoma (MRI scan is warranted if diagnosis is difficult);
4. The midline shift to less than 1 cm;
5. Attending physician makes a judgment that cerebral hernia would not occur and surgical operation might not be performed in a short time. Conservative treatment is adopted;
6. Patients have never undergo surgery on the hematoma;
7. Patient fully understood the nature of the study, and voluntarily participates and signs informed consent.

Exclusion Criteria:

1. Allergic to the statin and dexamethasone or its ingredients;
2. Hematoma caused by tumors, blood and other known comorbidities;
3. Abnormal liver function;
4. Uncontrolled hepatitis and other liver diseases, as well as suffering from other disease may interfere the study;
5. Patients have been on oral Statin treatment in the past four weeks;
6. Patients have been on oral Steroids treatment for a long time;
7. Diagnosed Diabetes patients with poorly controlled blood glucose
8. Participate in clinical trials in the past four weeks;
9. Pregnant or breastfeeding;
10. Failure of completing the trial by poor compliance;
11. For any reason, the researchers believe that the case is not suitable for inclusion.
Impact of Spontaneous Breathing on Ventilation Distribution in Obese Patients

General anesthesia (GA) and paralysis are factors which facilitate atelectasis formation, especially in obese patients. Spontaneous breathing can reduce the amount of atelectasis. In this study, the investigators are comaparing obese patients undergoing hip arthroplasty in GA versus spinal anesthesia. Distribution of ventilation during and after anesthesia is assessed by eletrical impedance tomography (EIT).


Eligibility Criteria:
Inclusion Criteria:

* BMI \>30
* age 18-85
* elective hip arthroplasty in general anesthesia or spinal anesthesia

Exclusion Criteria:

* pregnancy/breastfeeding
* allergies against drugs used for the anesthesia
* contraindications for EIT
* severe cardiac or pulmonary comorbidities
* unable to consent or understand/follow study
The Effects of Mild Sedation on Motor Function Networks in Patients With Brian Gliomas

It has been shown through functional MRI (Magnetic Resonance Imaging) that patients with gliomas in eloquent areas have compensated neurological function by virtue of brain post-injury reorganization. Our previous clinical research found that mild sedation could induce and/or exacerbate neurological deficits, especially in limb motor and ataxia function, in these patients presumably by impairing functional compensation,. Nevertheless it is still very unclear how mild sedation affects sensorimotor networks in brains where reorganization may be present. Since eloquent area glioma patients are frequently subjected to sedation, anesthetics, and neurological examinations perioperatively, it is important to investigate how mild sedation interacts with motor network reorganization and functional compensation. Our research in patients with eloquent area gliomas will utilize neurological evaluations and multimodal MRI to explore the changes in brain upper limb' motor network reorganization after mild sedation by different sedatives-anesthetics. The neurological evaluations include sensorimotor function scale and testing tool. Multimodal MRI consists of 3-dimentional structure, blood oxygen-level dependent for cortical activation and diffusion tensor imaging for subcortical conduction. The data from the clinical testing and functional MRI will be processed and analyzed along with other relevant clinical information. This research will answer the question of how mild sedation affects upper limb motor function networks in brains with eloquent area gliomas. This new information will help optimize perioperative anesthetic and sedative choice for patients with eloquent area gliomas.


Eligibility Criteria:
Inclusion Criteria:

* Age between 25 to 60 years old;
* Diagnosed as intracranial eloquent glioma by MRI, or healthy volunteer without any intracranial disease;
* Without history of chronic diseases;
* Without internal and/external metal object;
* Education background is beyond high school;
* Right handedness

Exclusion Criteria:

* Unable to cooperate the neurologic function evaluation;
* Neuropsychiatric disorders and/or taking antipsychotic medications;
* Drug and/or alcohol abuse;
* Receiving longterm sedatives and/or analgesics;
* Pregnant and/or lactation period patients;
* Present severe cardiovascular diseases;
* Having claustrophobia;
* Body mass index equal or more than 35 kg/m2;
* Anticipated difficult airway;
* History of severe obstructive sleep apnea;
* History of reflux
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment

This study has been designed in order to detect EGFR mutation abundance of tissue and concentration of plasma from Advanced Non-small Cell Lung Cancer during treatment with Tyrosine Kinase Inhibitor (TKI) .Through this experiment the investigators aim to evaluate the feasibility of plasma EGFR detection and evaluate the correlation of EGFR mutations and prognosis.


Eligibility Criteria:
Inclusion Criteria:

* Age older than 18 years and under 75 years
* Histologically and cytologically proven non-small Cell Lung Cancer
* Clinical stages Ⅲ \~ Ⅳ
* Not receive any anti-tumor treatment
* Eastern cooperative oncology group performance status (ECOG PS) =1\~2
* Estimated survival time more than 3 months
* EGFR-TKI treatment for first-line or second-line
* Voluntary to participate in this clinical trial and sign the consent form

Exclusion Criteria:

* Patients have received EGFR-TKI therapy before the study
* With other malignancy history in the recent 5 years before the study
* Pregnancy or breast feeding phase
* Inadequate samples for testing
* Follow-up compliance is poor
Investigating the Effectiveness of Exercise Coaching on the Physical Activity Behavior of Physically Inactive Employees.

The primary aim of this study is to investigate if and how a physical activity counselor can offer an added value in exercise promotion in physically inactive employees. We will explore if the physical activity counselor in the workplace setting can motivate sedentary employees to engage into systematic participation in sports and/or exercise by means of a short term coaching of 12 weeks. We aim to include 300 employees in the physical activity coaching process.

Being physically active on a regular basis has many health benefits. Nevertheless, the majority of the Belgian population doesn't reach the recommended amount and intensity of physical activity to profit from these health benefits. A physical activity counselor can possibly play a crucial role for these physically inactive individuals. He/she can design an individualized exercise program to stimulate the person to become lifelong physical active. Research has shown that exercise promotion at work can result in a lower absenteeism, prevention of burn-out and a positive corporate identity.

Eligibility Criteria:
Inclusion Criteria:

* Employee of Janssen Pharmaceutics Belgium
* Physically inactive lifestyle (not reaching 150 minutes of moderate-to-vigorous physical activity a week)
* PAR-Q questionnaire all answers negative, if one or more answers are positive a permission of a physician is necessary

Exclusion Criteria:

* none
Lianhua Qingke for the Rehabilitation of Patient With Omicron Infection

The patients with Omicron infection usually have fever, respiratory symptoms, tachycardia, headache, toothache, muscle soreness, physical decline, and so on, while others are asymptomatic patients. It is urgent to find drugs to improve the long-term rehabilitation of symptomatic patients with Omicron infection and decrease the duration of viral shedding in both symptomatic and asymptomatic patients. This study aims to investigate the efficacy and safety of Lianhua Qingke tablets in patients with Omicron infection. The duration of viral shedding and symptoms will be evaluated. 6-month follow-up will be performed to evaluate the effect of Lianhua Qingke on long-term rehabilitation of all symptoms induced by Omicron infection, as well as infection events.


Eligibility Criteria:
Inclusion Criteria:

* confirmed Omicron infection by virus testing;
* ≥18 years of age;
* informed consent provided.

Exclusion Criteria:

* overt bacterial infection in the respiratory tract resulting from common pathologies, including primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;
* asthma treated daily, chronic airway disease, respiratory bacterial infections (e.g., purulent tonsillitis), acute tracheobronchitis, sinusitis, otitis media, and further respiratory tract pathologies potentially affecting the trial's data analysis;
* common pulmonary diseases (e.g., severe pulmonary interstitial lesions and bronchiectasis) confirmed by chest CT;
* severe pneumonia requiring ventilator use;
* previous or present diseases potentially affecting trial participation or influencing study outcome, based on the investigator's judgment;
* pregnancy or lactation in women;
* participation in a clinical study in the past 3 months;
* history of allergy to ≥2 drugs or foods or known allergy to the drug's constituents.
PACE+: Counseling Adolescents for Exercise and Nutrition

PACE+ was developed to address the increased number of adolescents in our country that are at risk for cardiovascular disease, cancer, and other diseases due to inactivity, obesity, and malnourishment. PACE+ will evaluate the efficacy of an integrated clinical and home-based intervention to improve physical activity and nutrition behaviors in adolescents ages 11-15 over a period of 2 years.

This study is unique in that it will be one of the first to evaluate a combined physical activity and nutrition intervention for youth that revolves around the primary health care setting. The PACE+ intervention is particularly innovative in that three components - computer, provider counseling, and an extended home-based intervention - are unified through a common theoretical framework.

Improved physical activity (PA) and nutrition behaviors in adolescents show great promise to reduce risk of cancers and other diseases. Fewer than 20% of adolescents meet recommendations for fat or fruits \& vegetables consumption, and only 50% of adolescent girls and 67% of boys meet recommendations for vigorous PA. PACE+ will evaluate an integrated clinical and home-based intervention to improve physical activity (PA) and nutrition behaviors in adolescents. The intervention has three integrated components: a computer assessment and action planner; provider counseling; and 24 months of extended phone \& mail contact. 768 male and female adolescents age 11 through 15; will be recruited from six healthcare settings. Subjects will be randomly assigned within practices to two successive one-year "doses" of PACE+ or a comparison condition involving counseling for sun protection behaviors. PACE+ assesses four behaviors: 1) dietary fat, 2) fruits \& vegetable consumption, 3) physical activity, and 4) sedentary behavior. Primary behavioral outcomes, secondary outcomes, and selected mediators and process variables will be measured prior to the first office visit and at 6, 12 and 24 months. Primary outcomes will be measured by the 7-day physical activity recall and 3-day food record of fruits \& vegetables and fat at 12 months. Secondary outcomes include adiposity, fitness, BMI, psychosocial mediators of change, and body image. Potential risks are psychological and physical, however the risks are slight and of low likelihood. Benefits include helping bring about healthier lifestyles to prevent weight gain and reduce premature morbidity and mortality due to cancer, cardiovascular disease and other health problems. This study will be the first to evaluate a combined physical activity and nutrition intervention for youth that revolves around the primary health care setting.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must be in good general health and have the ability to read and speak English.

Exclusion Criteria:

* A known eating disorder,
* pregnancy,
* any cardiovascular or musculoskeletal problems that would limit their ability to comply with physical activity recommendations, and
* being in foster care (due to difficulty in obtaining follow-up measures).
Efficacy and Safety of MedifoamⓇ and BetafoamⓇ in Pressure Ulcer

This study aims to exploratively assess the efficacy and safety of hydrophilic polyurethane foam dressing (MedifoamⓇ or BetafoamⓇ) in pressure ulcer specifically. The target enrolment is 20 patients, with 10 patients per arm.

As the primary objective, the percentage of completely healed patients and the time to complete healing will be assessed after applying the study device, MedifoamⓇ or BetafoamⓇ, for 12 weeks to pressure ulcer patients. In addition, the pressure ulcer size reduction rate over 12 weeks will be evaluated.

Patients will make once weekly site visits. There are 14 visits in total, including a screening visit 14 days (maximum) before the baseline visit.

Eligibility Criteria:
Inclusion Criteria:

1. Adults aged at least 19 years old as of the consent date
2. Pressure ulcer of National Pressure Ulcer Advisory Panel (NPUAP) Stage III at screening
3. Pressure ulcer size of 3-10 cm2 at screening
4. Written consent provided by the subject or representative

Exclusion Criteria:

1. Any study ulcer of NPUAP Stage I, II or IV
2. Diabetic ulcer or venous ulcer (or stasis ulcer)
3. Past history of surgical treatment within 1 year or irradiation at the target pressure ulcer within 1 year
4. Hypersensitivity reaction to this product or povidone iodine
5. Hyperthyroidism or thyroid disorder requiring drug treatment
6. Signs of a current underlying systemic infection (sepsis/bacterial infection/tuberculosis) or cellulitis or osteomyelitis
7. Type 1 diabetes
8. Current malnutrition
9. Heavy smoker: Current smoking level of ≥1 pack (20 cigarettes)/day of tobacco
10. Drug or alcohol addiction
11. Requirement of immune-suppressants during the study, or current chemotherapy or radiotherapy
12. Application of other investigational product/medical device within 1 month prior to the investigational device application
13. Pregnant or breast-feeding women
14. Other renal, hepatic, neurological or immunological disorder that may interfere with the wound healing process, at the discretion of the Investigator
Effectiveness of Calcium and Vitamin D, With and Without Collagen Peptide, in Enhancing Bone Mineral Density on Postmenopausal Women With Osteopenia

Osteopenia is characterized by bone mineral density (BMD) being lower than normal but not reaching the osteoporosis threshold, poses a serious problem for women after menopause. Osteopenia is a precursor to osteoporosis that is associated with increased risk of fractures, morbidity, and mortality. Using strategies to improve or maintain bone density is important for preventing osteoporosis and its associated complications. The combination of collagen peptide (CP) with calcium and vitamin D supplementation may provide several ways to improve bone health. This study aims to provide preliminary evidence of the effectiveness of traditional medicine in improving bone health through the effectiveness of CP.

Osteopenia is characterized by bone mineral density (BMD) being lower than normal but not reaching the osteoporosis threshold, poses a serious problem for women after menopause. Osteopenia is a precursor to osteoporosis that is associated with increased risk of fractures, morbidity, and mortality. Using strategies to improve or maintain bone density is important for preventing osteoporosis and its associated complications. The combination of collagen peptide (CP) with calcium and vitamin D supplementation may provide several ways to improve bone health. This study aims to provide preliminary evidence of the effectiveness of traditional medicine in improving bone health through the effectiveness of CP.The study was single blinded randomized controlled trial, involving 30 post-menopausal women that were equally divided into two groups by computer generated simple random sampling technique. Group A received bioactive collagen peptide along with calcium lactate, and vitamin D3. The control group (Group B) consisted of 15 participants who were given a chewable tablet daily, containing 1.25 grams of calcium carbonate (equivalent to 500 mg of elemental calcium) and 400 IU of vitamin D3.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal patients
* (-1. 0\>T-score\>-2. 5)

Exclusion Criteria:

* fracture,
* primary hyperparathyroidism